Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.59 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701087 | 1.00 | CA2 (0.63) | CA2CA1ZDHHC7BIRC2LMNA | |
| SCHEMBL27768349 | 0.98 | CA2 (0.66) | CA2CA1ZDHHC7BIRC2LMNA | |
| Methylene Chloride SCHEMBL3096630 | 0.95 | CA2 (0.58) | CA2CA1ZDHHC7BIRC2LMNA | |
| SCHEMBL27846410 | 0.92 | CA2 (0.74) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL18597131 | 0.90 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2LMNA | |
| SCHEMBL21356682 | 0.90 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2LMNA | |
| SCHEMBL967598 | 0.90 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2LMNA | |
| SCHEMBL21356695 | 0.90 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2LMNA | |
| SCHEMBL21356697 | 0.90 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2LMNA | |
| SCHEMBL17199802 | 0.90 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | CA2 4634/4885CA1 4839/4885ZDHHC7 2052/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | CA2 4634/4885CA1 4839/4885ZDHHC7 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.